Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 180

Results For "X"

9462 News Found

TB Alliance partners with Lupin for non-exclusive anti-TB drug
Policy | September 06, 2021

TB Alliance partners with Lupin for non-exclusive anti-TB drug

According to WHO, over 1.5 million people died of TB in 2020


Omeza Collegen Matrix gets U.S. FDA approval
Biotech | September 03, 2021

Omeza Collegen Matrix gets U.S. FDA approval

This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care


CII awards Excellence in Energy efficiency to Sai Life Sciences API unit
Sustainability | September 03, 2021

CII awards Excellence in Energy efficiency to Sai Life Sciences API unit

The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL


Digital adoption in healthcare will see exponential growth: Wipro GE study
Healthcare | September 03, 2021

Digital adoption in healthcare will see exponential growth: Wipro GE study

Key trends indicate that AI-based solutions, cloud-based healthcare solutions and digital transformations will be the key in the years to come.


Phase 2 of Covaxin intranasal trials begin in Kanpur
Biotech | September 02, 2021

Phase 2 of Covaxin intranasal trials begin in Kanpur

The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract


Shilpa Medicare receives approval for 2-Deoxy-2-Glucose powder
News | September 01, 2021

Shilpa Medicare receives approval for 2-Deoxy-2-Glucose powder

The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients


Pharma tops India’s exports from SEZs
News | September 01, 2021

Pharma tops India’s exports from SEZs

As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational


Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis
Biotech | August 31, 2021

Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis

Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old


Visby Medical receives FDA approval and CLIA waiver for PCR sexual health test
Drug Approval | August 30, 2021

Visby Medical receives FDA approval and CLIA waiver for PCR sexual health test

The Visby Medical sexual health click test is the first instrument-free PCR test for the detection of chlamydia, gonorrhoea and trichomonas, with results available within 30 minutes, during the patient visit


European Commission grants market authorisation for BioMarin’s Voxzogo
Biotech | August 28, 2021

European Commission grants market authorisation for BioMarin’s Voxzogo

It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo